# Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection

> **NCT01509404** · PHASE4 · COMPLETED · sponsor: **Medical University of South Carolina** · enrollment: 40 (actual)

## Conditions studied

- Cytomegalovirus Disease

## Interventions

- **DRUG:** Valganciclovir
- **BIOLOGICAL:** CMV hyperimmune globulin
- **DRUG:** Valganciclovir

## Key facts

- **NCT ID:** NCT01509404
- **Lead sponsor:** Medical University of South Carolina
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2014-12
- **Final completion:** 2015-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2018-10-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01509404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01509404, "Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01509404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*